Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

Table 3 Survival analysis of related factors of 232 patients with poorly-differentiated gastric neoplasms

Classification	Median survival time (mo)	1-yr survival rate (%)	3-yr survival rate (%)	5-yr survival rate (%)
Age (yr)
< 60	12	37	11	5
≥ 60	15	52	18	5
Gender
Male	14	52	16	6
Female	10	29	13	3
Tumor number
Solitary	14	49	17	6
Multiple	5	33	0	0
Tumor diameter (cm)
0-5	19	58	23	9
> 5	12	40	13	5
Invasion
M1/S/MP2	17	60	23	6
Serosal	12	42	13	5
Tumor site
Cardia	16	58	9	0
Fundus	20	67	17	17
Body	15	57	30	11
Antrum	12	33	0	0
C + F	13	41	6	0
Other	15	57	26	13
Pathological type
Large cell NEC	16	54	18	9
Small cell NEC	13	34	19	9
MANEC	12	37	11	0
NR	14	52	16	5
Ki-67 index
20%-50%	12	47	26	6
50%-70%	14	57	12	1
> 70%	13	29	7	0
Endoscopic
Performance	14	67	17	0
Polypoid	16	54	25	8
Mucosal elevation
Ulcer	13	48	15	6
Other	10	36	14	3
LN metastasis
No	18	57	18	6
Yes	13	47	15	5
Distant metastasis
No	17	62	22	7
Yes	11	28	7	2
AJCC stage
I	60	100	100	14
II	31	73	41	8
III	16	58	17	5
IV	11	33	11	4
Treatment
Surgery	15	55	17	9
Chemotherapy	12	29	4	0
S + C	16	57	23	6
Other	10	33	11	0

S + C: Surgery plus Chemotherapy; C + F: Cardia + Fundus.

M¹: Mucosa; S: Submucosa.

MP²: Muscularis propria.

NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; NR: Not reported; AJCC: American Joint Committee on Cancer.